Change in the Estimated Useful Life of the Entocort Trademark Rights and Commencement of Amortization
First written in FY2023-Q3. 1 of 2 entries say "Advanced", first in FY2023. Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023AdvancedAnnual report
「The trademark rights for the product Entocort, held by our subsidiary Tillotts Pharma AG, had not been amortized because their useful life could not be determined. However, following the launch of generic products in some European countries, we estimated the remaining useful life at 13 years, representing the period over which the brand could be maintained, and began amortization.」
Following the launch of generic products, the remaining useful life of the Entocort trademark rights was estimated at 13 years, and the accounting treatment was changed from non-amortization to commencement of amortization. The impact on operating income and other items was a decrease of ¥285.295 million. - FY2023-Q3First statedAnnual report
「The trademark rights for the product Entocort, held by our subsidiary Tillotts Pharma AG, had not been amortized because their useful life could not be determined. However, following the launch of generic products in some European countries, we reasonably estimated the period over which the brand could be maintained and began amortization.」
Following the launch of generic products in some European countries, the accounting estimate for the Entocort trademark rights was changed from non-amortization to commencement of amortization. As a result, operating income, ordinary income and profit before income taxes for the cumulative third quarter decreased by ¥139.452 million, respectively.